Andreas Kronbichler
@kronbichlerlab.bsky.social
Nephrologist from Austria, physician-scientist with an interest to improve patient care
Pretty much everything was even surprising to us!
October 8, 2025 at 11:02 AM
Pretty much everything was even surprising to us!
Please also look at the Supplements for all the unique features of the case 😉
September 11, 2025 at 8:06 PM
Please also look at the Supplements for all the unique features of the case 😉
Absolute rarity; only once when the patient was double-positive and the MPO-ANCA became dominant!
August 13, 2025 at 7:40 PM
Absolute rarity; only once when the patient was double-positive and the MPO-ANCA became dominant!
Most will eventually turn anti-GBM antibody negative when established on dialysis! Otherwise, you might consider a dose of rituximab
August 13, 2025 at 7:15 PM
Most will eventually turn anti-GBM antibody negative when established on dialysis! Otherwise, you might consider a dose of rituximab
If kidney is lost and no extrarenal manifestation, there would be no indication to use RTX or CYC, right?
August 13, 2025 at 6:10 PM
If kidney is lost and no extrarenal manifestation, there would be no indication to use RTX or CYC, right?
I was also there and enjoyed the discussions a lot!
July 3, 2025 at 5:33 AM
I was also there and enjoyed the discussions a lot!
Don’t forget our podocytopathy study 🤣
April 1, 2025 at 8:10 PM
Don’t forget our podocytopathy study 🤣
Why is rituximab not an option?
It is the most effective treatment option.
I guess there is no experience combining TAC and AVA so far. But I would contact the company (Amgen/CSL Vifor)
It is the most effective treatment option.
I guess there is no experience combining TAC and AVA so far. But I would contact the company (Amgen/CSL Vifor)
January 22, 2025 at 4:16 PM
Why is rituximab not an option?
It is the most effective treatment option.
I guess there is no experience combining TAC and AVA so far. But I would contact the company (Amgen/CSL Vifor)
It is the most effective treatment option.
I guess there is no experience combining TAC and AVA so far. But I would contact the company (Amgen/CSL Vifor)
Yes, the Imperial team @kidneydoc101.bsky.social et al. pubmed.ncbi.nlm.nih.gov/28750930/ have published this great article!
Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy - PubMed
Class IV-S lupus nephritis is often associated with more necrosis and fewer subendothelial immune deposits compared to class IV-G lupus nephritis, suggestive of necrotising glomerular inflammation fou...
pubmed.ncbi.nlm.nih.gov
December 30, 2024 at 4:08 PM
Yes, the Imperial team @kidneydoc101.bsky.social et al. pubmed.ncbi.nlm.nih.gov/28750930/ have published this great article!
Probably also a scenario where I would prefer EuroLupus CYC over MMF as induction therapy!
December 30, 2024 at 12:26 PM
Probably also a scenario where I would prefer EuroLupus CYC over MMF as induction therapy!
Finally, our analysis provides evidence that PR3-ANCA positive patients have a greater likelihood to recover kidney function and the % difference increase was significant!
December 20, 2024 at 4:44 AM
Finally, our analysis provides evidence that PR3-ANCA positive patients have a greater likelihood to recover kidney function and the % difference increase was significant!
No difference was seen when we focused on the different GC regimens! That is an important conclusion as recent retrospective data questions the reduced-dose PEXIVAS regimen
December 20, 2024 at 4:43 AM
No difference was seen when we focused on the different GC regimens! That is an important conclusion as recent retrospective data questions the reduced-dose PEXIVAS regimen